Harrow Health, Inc. (HROW)
| Market Cap | 204.68M |
| Revenue (ttm) | 46.88M |
| Net Income (ttm) | -1.85M |
| Shares Out | 25.92M |
| EPS (ttm) | -0.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $7.95 |
| Previous Close | $7.56 |
| Change ($) | 0.39 |
| Change (%) | 5.16% |
| Day's Open | 7.49 |
| Day's Range | 7.01 - 7.98 |
| Day's Volume | 273,276 |
| 52-Week Range | 3.33 - 11.10 |
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHVILLE, Tenn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for...
Company Expects to Begin Phase 2 Clinical Study in the Third Quarter of 2021 Company Expects to Begin Phase 2 Clinical Study in the Third Quarter of 2021
The COVID-19 crisis has drastically transformed the fortune of the medical services industry. The industry has been witnessingsignificant demand for telemedicine-focused online medical services.
Harrow Health (HROW) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
NASHVILLE, Tenn., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt® formulation has been published in the Ameri...
NASHVILLE, Tenn., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow's Chief Executive Officer, and Andrew Boll, Harrow's Chief Financi...
Harrow Health, Inc. (HROW) CEO Mark Baum on Q3 2020 Results - Earnings Call Transcript
Harrow (HROW) delivered earnings and revenue surprises of 88.24% and 65.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
NASHVILLE, Tenn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2020. Please click here to review Harrow Health's Letter to ...
Harrow Health (NASDAQ: HROW) will be releasing its next round of earnings this Monday, November 09. For all of the relevant information, here is your guide for Monday's Q3 earnings announcement.
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHVILLE, Tenn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9, 2020, it will release third quarte...
Harrow Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
NASHVILLE, Tenn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Larry Van Horn to its Board of Directors.
As of late, it has definitely been a great time to be an investor Harrow Health.
NASHVILLE, Tenn., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference...
Harrow Health, Inc. (HROW) CEO Mark Baum on Q2 2020 Results - Earnings Call Transcript
Harrow (HROW) delivered earnings and revenue surprises of 80.00% and 36.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
On Monday, August 10, Harrow Health (NASDAQ: HROW) will release its latest earnings report.
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHVILLE, Tenn., July 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quar...
The study published in Clinical Ophthalmology shows equivalent clinical outcomes to separately dosed eyedrops and a strong patient preference for the ImprimisRx proprietary combination drop th...
NASHVILLE, Tenn., June 29, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it is set to join the small-cap Russell 2000® Index and the broad-market Russell 3...
Harrow Health (HROW) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Ha...
Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2020 Results - Earnings Call Transcript
Harrow (HROW) delivered earnings and revenue surprises of 0.00% and 16.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ImprimisRx customers will have free access to the entire suite of Doxy.me award-winning telemedicine services ImprimisRx customers will have free access to the entire suite of Doxy.me award-wi...
NASHVILLE, Tenn., March 17, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Teresa Sparks to its Board of Directors.
Harrow (HROW) delivered earnings and revenue surprises of -23.08% and -10.16%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health, Inc. (HROW) CEO Mark Baum on Q4 2019 Results - Earnings Call Transcript
Agreement expands locations served and access to new ImprimisRx formulations Agreement expands locations served and access to new ImprimisRx formulations
ImprimisRx will supply iOR with a series of unique formulations needed during outpatient surgery ImprimisRx will supply iOR with a series of unique formulations needed during outpatient surgery
ImprimisRx to supply VCNA with a series of surgical pharmaceutical formulations needed during ophthalmic surgery ImprimisRx to supply VCNA with a series of surgical pharmaceutical formulations...
Investors need to pay close attention to Harrow Health (HROW) stock based on the movements in the options market lately.
SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Ha...
Harrow Health, Inc. (HROW) CEO Mark Baum on Q3 2019 Results - Earnings Call Transcript
Harrow (HROW) delivered earnings and revenue surprises of -2.27% and -4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join t...
BOSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer, ...
SAN DIEGO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Ha...
About HROW
Harrow Health, together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye dro... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1998 |
| CEO Mark L. Baum | Employees 133 |
| Stock Exchange NASDAQ | Ticker Symbol HROW |
Financial Performance
In 2019, Harrow Health's revenue was $51.17 million, an increase of 23.67% compared to the previous year's $41.37 million. Earnings were $168,000, a decrease of -98.85%.
Analyst Forecasts
According to 2 analysts, the average rating for Harrow Health stock is "Strong Buy." The 12-month stock price forecast is 13.50, which is an increase of 69.81% from the latest price.